


## Angiotensin I/II (1-6) (TFA)

<b>Cat. No.:</b>	HY-P1829A
<b>Molecular Formula:</b>	C <sub>38</sub> H <sub>56</sub> F <sub>3</sub> N <sub>11</sub> O <sub>12</sub>
<b>Molecular Weight:</b>	915.91
<b>Sequence:</b>	Asp-Arg-Val-Tyr-Ile-His
<b>Sequence Shortening:</b>	DRVYIH
<b>Target:</b>	Angiotensin Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Sealed storage, away from moisture and light
	Powder    -80°C    2 years
	-20°C    1 year



\* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 100 mg/mL (109.18 mM; Need ultrasonic)  
 DMSO : ≥ 100 mg/mL (109.18 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.0918 mL	5.4591 mL	10.9181 mL
	5 mM	0.2184 mL	1.0918 mL	2.1836 mL
	10 mM	0.1092 mL	0.5459 mL	1.0918 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Angiotensin I/II (1-6) TFA contains the amino acids 1-6 and is converted from Angiotensin I/II peptide. The precursor angiotensinogen is cleaved by renin to form angiotensin I. Angiotensin I is hydrolyzed by angiotensin-converting enzyme (ACE) to form the biologically active angiotensin II. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy<sup>[1][2][3]</sup>.

#### In Vitro

Angiotensin II is a naturally occurring octapeptide hormone component of the renin-angiotensin-aldosterone system (RAAS) and is a potent vasoconstrictor. Angiotensin II has important roles in cardiovascular, neurologic, and renal physiology, including maintenance of blood pressure, thirst sensation, response to the baroreceptor reflex, determination of renal blood flow and glomerular filtration rate, and electrolyte and free water homeostasis<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Erdős EG, et al. Conversion of angiotensin I to angiotensin II. Am J Med. 1976 May 31;60(6):749-59.
- [2]. Busse LW, et al. Clinical Experience With IV Angiotensin II Administration: A Systematic Review of Safety. Crit Care Med. 2017;45(8):1285-1294.
- [3]. Angiotensin II.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA